CoChat

Treatment of Autism Spectrum Disorder in Children and Adolescents

Open access
DeFilippis, Melissa, Wagner, Karen Dineen · 2025 · Psychopharmacology Bulletin
Cited by 177

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Autism spectrum disorder is a diagnosis that includes significant social communication deficits/delays along with restricted patterns of interests and behaviors. The prevalence of this diagnosis has increased over the past few decades, and it is unclear whether this is solely attributable to the increased awareness of milder forms of the disorder among medical providers. The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis. Children and adolescents with autism spectrum disorder appear to be more susceptible to adverse effects with medications; therefore, initiation with low doses and titrating very slowly is recommended. Some complementary alternative treatments have been researched as possible treatments in autism, though evidence supporting many of these is very limited.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.64719/pb.4346

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 107

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth. Arlington, VA: American Psychiatric Publishing; 2013. · DOI · Paper page
  2. Lai MC, Lombardo MV, Baron-Cohen S Autism. The Lancet. 2014;383:896–910. · DOI · Paper page
  3. Volkmar F, Siegel M, Woodbury-Smith M et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2014;53(2):237–257. · DOI · Paper page
  4. Blumberg SJ, Bramlett MD, Kogan MD et al. Changes in prevalence of parent-reported autism spectrum disorder in school-aged US Children: 2007 to 2011–2012. National Health Statistics Reports. 2013;65:1–11.
  5. Landa R. Early communication development and intervention for children with autism. Mental Retardation and Developmental Disabilities Research Reviews. 2007;13(1):16–25. · DOI · Paper page
  6. Ingersoll B, Schreibman L. Teaching reciprocal imitation skills to young children with autism using a naturalistic behavioral approach: effects on language, pretend play, and joint attention. Journal of Autism and Developmental Disorders. 2006;36(4):487–505. · DOI · Paper page
  7. Koegel LK, Koegel RL, Harrower JK. Pivotal response intervention I: overview of approach. Research and Practice for Persons with Severe Disabilities. 1999;24(3):174–185. · DOI · Paper page
  8. Hardan AY, Gengoux GW, Berquist KL et al. A randomized controlled trial of pivotal response treatment group for parents of children with autism. The Journal of Child Psychology and Psychiatry. 2015;56(8):884–892. · DOI · Paper page
  9. Mohammadzaheri F, Koegel LK, Rezaee M, Rafiee SM. A randomized clinical trial comparison between pivotal response treatment (PRT) and structured applied behavior analysis (ABA) for children with autism. Journal of Autism and Developmental Disorders. 2014;44:2769–2777. · DOI · Paper page
  10. Mohammadzaheri F, Koegel LK, Rezaei M, Bakhshi E. A randomized clinical trial comparison between pivotal response treatment (PRT) and adult-driven applied behavior analysis (ABA) intervention on disruptive behaviors in public school children with autism. Journal of Autism and Developmental Disorders. 2015;45:2899–2907. · DOI
  11. Landa RJ, Holman KC, O’Neill AH, Stuart EA. Intervention targeting development of socially synchronous engagement in toddlers with autism spectrum disorder: a randomized controlled trial. Journal of Child Psychology and Psychiatry. 2011;52(1):13–21. · DOI · Paper page
  12. Oosterling I, Visser J, Swinkels S et al. Randomized controlled trial of the focus parent training for toddlers with autism: 1-year outcome. Journal of Autism and Developmental Disorders. 2010;40:1447–1458. · DOI · Paper page
  13. Wetherby AM, Guthrie W, Woods J et al. Parent-implemented social intervention for toddlers with autism: an RCT. Pediatrics. 2014;134(6):1084–1093. · DOI · Paper page
  14. Kasari C, Lawton K, Shih W et al. Caregiver-mediated intervention for low-resourced preschoolers with autism: an RCT. Pediatrics. 2014;134(1):e72–e79. · DOI · Paper page
  15. Otero TL, Schatz RB, Merrill AC, Bellini S. Social skills training for youth with autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America. 2015;24(1):99–115. · DOI
  16. White SW, Koenig K, Scahill L. Social skills development in children with autism spectrum disorders: a review of the intervention research. Journal of Autism and Developmental Disorders. 2007;37:1858–1868. · DOI · Paper page
  17. Whalon KJ, Conroy MA, Martinez JR, Werch BL. School-based peer-related social competence interventions for children with autism spectrum disorder: a meta-analysis and descriptive review of single case research design studies. Journal of Autism and Developmental Disorders. 2015;45:1513–1531. · DOI
  18. Van Steensel FJA, Bogels SM. CBT for anxiety disorders in children with and without autism spectrum disorders. Journal of Consulting and Clinical Psychology. 2015;83(3):512–523. · DOI · Paper page
  19. Storch EA, Lewin AB, Collier AB et al. A randomized controlled trial of cognitive-behavioral therapy versus treatment as usual for adolescents with autism spectrum disorders and comorbid anxiety. Depression and Anxiety. 2015;32(3):174–181. · DOI · Paper page
  20. Aman MG, Sing NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency. 1985;89:485–491. · DOI · Paper page
  21. Shea S, Turgay A, Carroll A et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634–e641. · DOI · Paper page
  22. Schopler E, Mesibov GB, Renner BR. Los Angeles, CA: Western Psychological Press; 1988. The Childhood Autism Rating Scale (CARS)
  23. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry. 2005;162(7):1361–1369. · DOI · Paper page
  24. Troost P, Lahuis B, Steenhuis MP et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44(11):1137–1144. · DOI · Paper page
  25. Aman M, Rettiganti M, Nagaraja H et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology. 2015;25(6):482–493. · DOI · Paper page
  26. Miral S, Gencer O, Inal-emiroglu FN et al. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child and Adolescent Psychiatry. 2008;17(1):1–8. · DOI
  27. McDougle CJ, Scahill L, Aman MG et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psyhchopharmacology. American Journal of Psychiatry. 2005;162(2):1142–1148. · DOI · Paper page
  28. Freeman BJ, Ritvo ER, Yokota A, Rivo A. A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the Academy of Child and Adolescent Psychiatry. 1986;25:130–136. · DOI
  29. Williams S, Scahill L, Vitiello B et al. Risperidone and adaptive behavior in children with autism. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45(4):431–439. · DOI
  30. Marcus R, Owen R, Kamen L et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48(11):1110–1119. · DOI · Paper page
  31. Findling RL, Mankoski R, Timko K et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry. 2014;75(1):22–30. · DOI · Paper page
  32. Hollander E, Wasserman S, Swanson EN et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology. 2006;16(5):541–548. · DOI · Paper page
  33. Kemner C, Willemsen-Swinkels S, De Jonge M et al. Open-label study of olanzapine in children with pervasive developmental disorder. Journal of Clinical Psychopharmacology. 2002;22(5):455–460. · DOI
  34. Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Medical Principles and Practice. 2008;17:415–418. · DOI
  35. Loebel A, Brams M, Goldman RS et al. Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders. 2016;46:1153–1163. · DOI · Paper page
  36. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology. 1999;9(2):99–107. · DOI · Paper page
  37. Findling RL, McNamara NK, Gracious BL et al. Quetiapine in nine youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology. 2004;14(2):287–294. · DOI · Paper page
  38. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clinical Neuropharmacology. 2011;34(6):216–219. · DOI
  39. Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. Journal of Child and Adolescent Psychopharmacology. 2007;17(6):779–790. · DOI · Paper page
  40. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41(8):921–927. · DOI · Paper page
  41. Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology. 2012;223:237–245. · DOI
  42. Campbell M, Anderson LT, Small AM et al. The effects of haloperidol on learning and behavior in autistic children. Journal of Autism and Developmental Disorders. 1982;12(2):167–175. · DOI
  43. Anderson LT, Campbell M, Grega DM et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. American Journal of Psychiatry. 1984;141(10):1195–1202. · DOI · Paper page
  44. Anderson LT, Campbell M, Adams P et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders. 1989;19(2):227–239. · DOI · Paper page
  45. Perry R, Campbell M, Adams P et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. Journal of the American Academy of Child and Adolescent Psychiatry. 1989;28(1):87–92. · DOI · Paper page
  46. Campbell M, Armenteros JL, Malone RP et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. Journal of the American Association of Child and Adolescent Psychiatry. 1997;36(6):835–843. · DOI · Paper page
  47. Hollander E, Phillips A, Chaplin W et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30:582–589. · DOI · Paper page
  48. Study of Fluoxetine in Autism (SOFIA) Autism Speaks Press Release, February 18, 2009. 2016 May 6; Available online at: http://www.autismspeaks.org/about-us/press-releases/autism-speaks-announces-results-reported-study-fluoxetine-autism-sofia.
  49. Cook EH, Jr, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry. 1992;31(4):739–745. · DOI · Paper page
  50. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord. 2000;30:427–435. · DOI · Paper page
  51. Martin A, Koenig K, Anderson GM, Scahill L. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. Journal of Autism and Developmental Disorders. 2003;33(1):77–85. · DOI
  52. Owley T, Walton L, Salt J et al. An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44(4):343–348. · DOI
  53. Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. Journal of Child Neurology. 2000;15(2):132–135. · DOI · Paper page
  54. Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology. 2001;11(3):267–277. · DOI · Paper page
  55. Sanchez L, Campbell M, Small A et al. A pilot study of clomipramine in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry. 1996;35(4):537–544. · DOI · Paper page
  56. Brasic JR, Barnett JY, Sheitman BB et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 1994;44(7):1309–1312. · DOI · Paper page
  57. Gordon CT, State RC, Nelson JE et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry. 1993;50:441–447. · DOI · Paper page
  58. Hollander E, Chaplin W, Soorya L et al. Divalproex sodium vs. placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35:990–998. · DOI · Paper page
  59. Hollander E, Soorya L, Wasserman S et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. International Journal of Neuropsychopharmacology. 2006;9:209–213. · DOI · Paper page
  60. Belsito KM, Law PA, Kirk KS, Lana RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders. 2001;31(2):175–181. · DOI · Paper page
  61. Pearson DA, Santos CW, Aman MG et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism Spectrum disorders and AHDD symptoms. Journal of Child and Adolescent Psychopharmacology. 2013;23(5):337–351. · DOI · Paper page
  62. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders. 2000;30(3):245–255. · DOI · Paper page
  63. Quintana H, Birmaher B, Stedge D et al. Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders. 1995;25(3):287–294. · DOI · Paper page
  64. Harfterkamp M, Buitelaar JK, Minderaa RB et al. Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change. Journal of Child and Adolescent Psychopharmacology. 2014;24(9):481–485. · DOI
  65. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry. 1992;53(3):77–82.
  66. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, van Engeland Herman. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Research. 1995;58:203–215. · DOI
  67. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry. 1995;34(2):223–231. · DOI
  68. Willemsen-Swinkels SHN, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biological Psychiatry. 1996;39:1023–1031. · DOI
  69. Feldman HM, Kolmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. Journal of the Academy of Child and Adolescent Psychiatry. 1999;38(5):587–593. · DOI
  70. Campbell M, Anderson LT, Small AM et al. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacology Bulletin. 1990;26(1):130–135.
  71. Guastella AJ, Einfeld SL, Gray KM et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biological Psychiatry. 2010;67:692–694. · DOI · Paper page
  72. Chez MG, Buchanan TM, Becker M et al. Donepezil hydrochloride: a double-blind study in autistic children. Journal of Pediatric Neurology. 2003;1(2):83–88.
  73. Geier DA, Kern JK, Davis G et al. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Medical Science Monitor. 2011;17(6):PI15–PI23. · DOI · Paper page
  74. Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. The British Medical Journal. 201202;325:1422. · DOI · Paper page
  75. King BH, Wright DM, Handen BL et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40(6):658–665. · DOI · Paper page
  76. Veenstra-Vanderweele J, Sikich L, Melmed R et al. Randomized, controlled, phase 2 trial of STX209 for social function in autism spectrum disorder. International Society of Autism Research Annual Meeting. 2013;102:001.
  77. Wasserman S, Iyengar R, Chaplin WF et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology. 2006;21(6):363–367. · DOI · Paper page
  78. Akhondzadeh S, Fallah J, Mohammadi M et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010;34:32–36. · DOI
  79. Nikoo M, Radnia H, Rarokhnia M et al. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical Neuropharmacology. 2015;38(1):11–17. · DOI · Paper page
  80. Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of n-acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry. 2013;13(196):1–7. · DOI · Paper page
  81. Ghaleiha A, Mohammadi E, Mohammadi M et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Pediatric Drugs. 2013;15:505–514. · DOI
  82. Ghaleiha A, Asadabadi M, Mohammadi M et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology. 2013;16:783–789. · DOI · Paper page
  83. Mohammadi M, Yadegari N, Hassanzadeh E et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology. 2013;36(6):179–184. · DOI · Paper page
  84. Asadabadi M, Mohammadi M, Ghanizadeh A et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology. 2013;225:51–59. · DOI
  85. Ghaleiha A, Rasa SM, Nikoo M et al. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Research. 2015;229:181–187. · DOI
  86. Ghanizadeh A, Ayoobzadehshirazi A. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology. 2015;52:77–81. · DOI
  87. Akhondzadeh S, Erfani S, Mohammadi M et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 2004;29:145–150. · DOI
  88. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. Journal of Sleep Research. 2012;21:700–709. · DOI · Paper page
  89. Wright B, Sims D, Smart S et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. Journal of Autism and Developmental Disorders. 2011;41:175–184. · DOI · Paper page
  90. Wirojanan J, Jacquemont S, Diaz R et al. The efficacy of melatonin for sleep problems in children with autism, fragile x syndrome, or autism and fragile x syndrome. Journal of Clinical Sleep Medicine. 2009;5(2):145–150. · DOI · Paper page
  91. Wasdell MB, Jan JE, Bomben MM et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. Journal of Pineal Research. 2008;44:57–64. · DOI · Paper page
  92. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child: Care, Health and Development. 2006;32(5):585–589. · DOI · Paper page
  93. Bent S, Hendren RL, Zandi T et al. Internet-based, randomized controlled trial of omega-3 fatty acids for hyperactivity in autism. Journal of the American Academy of Child and Adolescent Psychiatry. 2014;53(6):658–666. · DOI · Paper page
  94. Bertoglio K, James SJ, Deprey L et al. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. The Journal of Alternative and Complementary Medicine. 2010;16(5):555–560. · DOI · Paper page
  95. Hendren RL, James SJ, Widjaja F et al. Randomized, placebo-controlled trial of methyl B12 for children with autism. Journal of Child and Adolescent Psychopharmacology. 2006 Feb 18; [Epub ahead of print]
  96. Hardan AU, Fung LK, Libove RA et al. A randomized controlled pilot trial of oral n-acetylcysteine in children with autism. Biological Psychiatry. 2012;71:956–961. · DOI · Paper page
  97. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. The Journal of Alternative and Complementary Medicine. 2004;10(6):1033–1039. · DOI · Paper page
  98. Adams JB, Audhya T, McDonough-Means S et al. Effect of a vitamin/mineral supplement on children and adults with autism. BioMed Central Pediatrics. 2011;11:1–30. · DOI · Paper page
  99. Munasinghe S, Oliff C, Finn J, Wray J. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial. Journal of Autism and Developmental Disorders. 2010;40:1131–1138. · DOI
  100. Hyman SL, Stewart PA, Foley J et al. The gluten-free/casein-free diet: a double-blind challenge trial in children with autism. Journal of Autism and Developmental Disorders. 2016;46(1):205–220. · DOI · Paper page
  101. Gupta S. Treatment of children with autism with intravenous immunoglobulin. Journal of Child Neurology. 1999;14(3):203–205.
  102. DelGiudice-Asch G, Simon L, Schmeidler J et al. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. Journal of Autism and Developmental Disorders. 1999;29(2):157–160. · DOI
  103. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. Journal of Child Neurology. 1998;13(2):79–82. · DOI · Paper page
  104. Hendren RL. Autism: biomedical complementary treatment approaches. The Child and Adolescent Psychiatric Clinics of North America. 2013;22(3):443–456. · DOI
  105. Adams JB, Baral M, Geis E et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B – behavioral results. BioMed Central Pharmacology. 2009;9(17):1–9. · DOI
  106. Adams JB, Baral M, Geis E et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A – medical results. BioMed Central Pharmacology. 2009;9(16):1–22. · DOI · Paper page
  107. Brent J. Commentary on the abuse of metal chelation therapy in patients with autism spectrum disorders. Journal of Medical Toxicology. 2013;9:370–372. · DOI

Cited by

See all 177

Metadata

Authors
DeFilippis, M., & Wagner, K. D.
Venue
Psychopharmacology Bulletin
Published
2025-08-12
Volume
46
Issue
2
Pages
18-41
ISSN
  • 0048-5764 (ISSN-L)
  • 2472-2448
OpenAlex
W2540591581
Cited by
177
References
39
FWCI
16.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.